The stock has a 36-month beta value of 0.84. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BVS is 36.10M, and at present, short sellers hold a 1.57% of that float. On July 04, 2024, the average trading volume of BVS was 432.37K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BVS) stock’s latest price update
Bioventus Inc (NASDAQ: BVS)’s stock price has plunge by 2.25relation to previous closing price of 5.78. Nevertheless, the company has seen a 5.54% surge in its stock price over the last five trading sessions. zacks.com reported 2024-06-05 that Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.
BVS’s Market Performance
Bioventus Inc (BVS) has experienced a 5.54% rise in stock performance for the past week, with a -11.79% drop in the past month, and a 17.73% rise in the past quarter. The volatility ratio for the week is 6.25%, and the volatility levels for the past 30 days are at 5.76% for BVS. The simple moving average for the past 20 days is -3.17% for BVS’s stock, with a 26.04% simple moving average for the past 200 days.
Analysts’ Opinion of BVS
Many brokerage firms have already submitted their reports for BVS stocks, with Canaccord Genuity repeating the rating for BVS by listing it as a “Buy.” The predicted price for BVS in the upcoming period, according to Canaccord Genuity is $7 based on the research report published on December 07, 2023 of the previous year 2023.
Craig Hallum, on the other hand, stated in their research note that they expect to see BVS reach a price target of $6, previously predicting the price at $4. The rating they have provided for BVS stocks is “Buy” according to the report published on August 09th, 2023.
BVS Trading at 3.97% from the 50-Day Moving Average
After a stumble in the market that brought BVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.05% of loss for the given period.
Volatility was left at 5.76%, however, over the last 30 days, the volatility rate increased by 6.25%, as shares sank -12.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.30% upper at present.
During the last 5 trading sessions, BVS rose by +5.18%, which changed the moving average for the period of 200-days by +93.11% in comparison to the 20-day moving average, which settled at $6.06. In addition, Bioventus Inc saw 12.14% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BVS starting from Singleton Mark Leonard, who sale 9,219 shares at the price of $5.57 back on Jun 21 ’24. After this action, Singleton Mark Leonard now owns 84,895 shares of Bioventus Inc, valued at $51,350 using the latest closing price.
D’Adamio Anthony, the SVP & General Counsel of Bioventus Inc, sale 5,904 shares at $5.57 during a trade that took place back on Jun 21 ’24, which means that D’Adamio Anthony is holding 95,576 shares at $32,885 based on the most recent closing price.
Stock Fundamentals for BVS
Current profitability levels for the company are sitting at:
- 0.04 for the present operating margin
- 0.65 for the gross margin
The net margin for Bioventus Inc stands at -0.04. The total capital return value is set at 0.03. Equity return is now at value -12.03, with -2.57 for asset returns.
Based on Bioventus Inc (BVS), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at 0.01. The debt to equity ratio resting at 2.31. The interest coverage ratio of the stock is 0.47.
Currently, EBITDA for the company is 73.38 million with net debt to EBITDA at 5.1. When we switch over and look at the enterprise to sales, we see a ratio of 1.45. The receivables turnover for the company is 4.16for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.53.
Conclusion
To sum up, Bioventus Inc (BVS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
